OTC Triptans in Germany

Date: July 17, 2012
Pages: 27
Price:
US$ 990.00
Publisher: Euromonitor International Ltd
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O66E6DF292BEN
Leaflet:

Download PDF Leaflet

2011 saw the introduction of a second product in the category in Germany; Dolortriptan, with the active ingredient almotriptan, was introduced by Johnson & Johnson GmbH. This launch and the continued growth of Formigran (GlaxoSmithKline GmbH & Co KG) were responsible for a considerable further increase of category value sales in Germany in 2011.

Euromonitor International's OTC Triptans in Germany report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2007-2011, allowing you to identify the sectors driving growth. Forecasts to 2016 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the OTC Triptans market;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
OTC TRIPTANS IN GERMANY

Euromonitor International
July 2012

LIST OF CONTENTS AND TABLES

Headlines
Trends
Switches
Competitive Landscape
Prospects
Category Data
  Table 1 Sales of OTC Triptans: Value 2006-2011
  Table 2 Sales of OTC Triptans: % Value Growth 2006-2011
  Table 3 OTC Triptans Company Shares by Value 2007-2011
  Table 4 OTC Triptans Brand Shares by Value 2008-2011
  Table 5 Forecast Sales of OTC Triptans: Value 2011-2016
  Table 6 Forecast Sales of OTC Triptans: % Value Growth 2011-2016
GlaxoSmithKline GmbH & Co Kg in Consumer Health (germany)
Strategic Direction
Key Facts
  Summary 1 GlaxoSmithKline GmbH & Co KG: Key Facts
  Summary 2 GlaxoSmithKline GmbH & Co KG: Operational Indicators
Company Background
Production
  Summary 3 GlaxoSmithKline GmbH & Co KG: Production Statistics 2011
Competitive Positioning
  Summary 4 GlaxoSmithKline GmbH & Co KG: Competitive Position 2011
Johnson & Johnson GmbH in Consumer Health (germany)
Strategic Direction
Key Facts
  Summary 5 Johnson & Johnson GmbH: Key Facts
  Summary 6 Johnson & Johnson GmbH: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 7 Johnson & Johnson GmbH: Competitive Position 2011
Executive Summary
Consumer Health Overall Stagnating in Germany in 2011
Market Under Pressure From Healthier Diets and More Exercise
Very Fragmented Market Continues To Be Led by Bayer Vital
Consumer Healthcare Most Often Sold in Health and Beauty Retailers
Small Decline of Consumer Health Expected Over Forecast Period in Germany
Key Trends and Developments
Ongoing Relatively Favourable Economic Conditions in Germany in 2011
Demographic Changes Continue To Influence Consumer Health in Germany
Increasing Shares of Sales Through Internet Retailing in Consumer Health
Consumer Lifestyle Issues Offer Opportunities for Manufacturers and Retailers
Innovation Essential for Premium Brands To Thrive in Consumer Health
Market Indicators
  Table 7 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  Table 8 Life Expectancy at Birth 2006-2011
Market Data
  Table 9 Sales of Consumer Health by Category: Value 2006-2011
  Table 10 Sales of Consumer Health by Category: % Value Growth 2006-2011
  Table 11 Consumer Health Company Shares 2007-2011
  Table 12 Consumer Health Brand Shares 2008-2011
  Table 13 Penetration of Private Label by Category 2006-2011
  Table 14 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  Table 15 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  Table 16 Forecast Sales of Consumer Health by Category: Value 2011-2016
  Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Switches
  Summary 8 OTC - Switches 2010-2011
Definitions
Sources
  Summary 9 Research Sources
Skip to top


OTC Triptans in New Zealand US$ 990.00 Jul, 2013 · 31 pages
OTC Triptans - New Zealand US$ 900.00 Jul, 2010 · 35 pages
OTC Triptans - Venezuela US$ 990.00 Aug, 2009 · 28 pages
OTC Triptans in the United Kingdom US$ 990.00 Jul, 2013 · 30 pages

Ask Your Question

OTC Triptans in Germany
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: